Research advances in adoptive cell transfer immunotherapy for hepatocellular carcinoma
10.3969/j.issn.1001-5256.2020.08.038
- VernacularTitle:肝细胞癌过继细胞免疫治疗研究进展
- Author:
Yan LI
1
;
Huling YAN
1
;
Ying SHI
1
;
Di ZHANG
1
;
Xiaolun HUANG
1
Author Information
1. Cell Transplant Center, The Affiliated Hospital of University of Electronic Science and Technology of China & Sichuan Provincial People’s Hospital, Chengdu 610041, China
- Publication Type:Research Article
- Keywords:
carcinoma, hepatocellular;
immunotherapy, adoptive;
therapeutics
- From:
Journal of Clinical Hepatology
2020;36(8):1852-1857
- CountryChina
- Language:Chinese
-
Abstract:
The mortality rate of liver cancer patients in China is increasing constantly, which greatly threatens human health, and therefore, it is urgent to explore more effective treatment methods to prolong the survival time of patients. Because of its special physiological structure, the liver plays an immunoregulatory role, and thus immunotherapy for liver cancer gradually shows its clinical advantages and has become the fourth-generation therapy for liver cancer after surgical resection, chemotherapy, and radiotherapy. Adoptive cell transfer immunotherapy has been developed rapidly in the treatment of hepatocellular carcinoma (HCC) in recent years. CIK, NK, DC-CIK, TIL, and CAR-T cells are immune cells used for adoptive cell transfer immunotherapy. This article briefly summarizes the research advances in these immune cells in the treatment of HCC.
